AOP-Wiki

API

All Key Events

Showing 1826 to 1850 of 1936 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

178	Mitochondrial electron transport chain, disrupted Short Name	1	Cellular	Nov 29, 2016	Jan 7, 2026	4 AOPs 26: Calcium-mediated neuronal ROS production and energy imbalance 284: Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress leads to chronic kidney disease 564: DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. 590: Increase of intracellular copper leading to cuproptosis via interference with energy metabolism
1862	Decrease, Photosystem II efficiency Short Name Decrease, Photosystem II efficiency	0	Cellular	Apr 11, 2021	Jan 16, 2026	3 AOPs 386: Deposition of ionizing energy leading to population decline via inhibition of photosynthesis 389: Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
1475	Decrease, Photosynthesis Short Name Decrease, Photosynthesis	0	Cellular	Oct 10, 2017	Jan 20, 2026	4 AOPs 245: Reduction in photophosphorylation leading to growth inhibition in aquatic plants 386: Deposition of ionizing energy leading to population decline via inhibition of photosynthesis 389: Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
1065	Activation, estrogen receptor alpha Short Name Activation, ERα	2	Molecular	Nov 29, 2016	Jan 28, 2026	11 AOPs 445: Estrogen Receptor Alpha Agonism leads to Impaired Reproduction 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level 561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol 565: 17β-Hydroxysteroid dehydrogenase 2, inhibition leading to activation, estrogen receptor alpha 609: Activation, estrogen receptor alpha leads to prolonged estrus cycle via decreased kisspeptin release 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release 637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining 639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release 640: Activation, estrogen receptor alpha leads to decreased fertility via prolonged estrus cycle 641: Activation, estrogen receptor alpha leads to increased, phenotypic female-biased sex ratio via increased, differentiation to ovaries
530	Decreased, GnRH pulsatility/release Short Name Decreased, GnRH pulsatility/release	1	Cellular	Nov 29, 2016	Jan 28, 2026	4 AOPs 73: Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity 126: Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation 566: Decreased, GnRH pulsatility/release leading to estradiol availability, increased via impaired ovulation 609: Activation, estrogen receptor alpha leads to prolonged estrus cycle via decreased kisspeptin release
2306	Persistent vaginal cornification Short Name Persistent vaginal cornification	1	Tissue	Jan 13, 2025	Jan 29, 2026	2 AOPs 566: Decreased, GnRH pulsatility/release leading to estradiol availability, increased via impaired ovulation 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release
1545	Decreased, mitochondrial oxidative phosphorylation Short Name	0	Cellular	Dec 19, 2018	Feb 4, 2026	2 AOPs 273: Mitochondrial complex inhibition leading to liver injury 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
1472	Decrease, ATP production Short Name Decrease, ATP production	1	Cellular	Oct 10, 2017	Feb 4, 2026	5 AOPs 245: Reduction in photophosphorylation leading to growth inhibition in aquatic plants 386: Deposition of ionizing energy leading to population decline via inhibition of photosynthesis 389: Oxygen-evolving complex damage leading to population decline via inhibition of photosynthesis 387: Deposition of ionising energy leading to population decline via mitochondrial dysfunction 567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
2307	Binding of plastoquinone B (QB) within D1 protein of Photosystem II Short Name Binding to the QB site D1 protein	0	Molecular	Jan 14, 2025	Feb 4, 2026	567: Binding to plastoquinone B site leading to decreased population growth rate via photosystem II inhibition
2403	Metabolic impairment Short Name Metabolic impairment	0	Cellular	Feb 6, 2026	Feb 6, 2026	622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
1346	Increased, depression Short Name Increased, depression	0	Individual	Apr 13, 2017	Feb 6, 2026	4 AOPs 214: Network of SSRIs (selective serotonin reuptake inhibitors) 221: Mental stress to depression 224: Serotonin transporter activation to depression 604: Binding of Alpha 1-Adrenergics to Agonists Leading to Depression
2401	Male preputial separation, failed/delayed Short Name Male PPS, failed/delayed	2	Tissue	Dec 15, 2025	Feb 6, 2026	619: Androgen receptor antagonism leads to delayed preputial separation via reduced fibroblast growth factor in genital-tubercle tissues
1272	Increase, Myofibroblast expansion Short Name Increase, Myofibroblast expansion	0	Cellular	Feb 15, 2017	Feb 10, 2026	None
1306	Increase, De novo lipogenesis Short Name Increase, De novo lipogenesis	0	Cellular	Apr 12, 2017	Feb 10, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2405	Increase, Hepatocellular lipotoxicity Short Name Increase, Hepatocellular lipotoxicity	0	Cellular	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
1898	Increase, Damage-associated molecular pattern release Short Name Increase, DAMP release	0	Tissue	Jul 8, 2021	Feb 10, 2026	377: Dysregulated prolonged Toll Like Receptor 9 (TLR9) activation leading to Multi Organ Failure involving Acute Respiratory Distress Syndrome (ARDS)
1501	Increase, Extracellular matrix deposition Short Name Increase, ECM deposition	0	Tissue	Jan 5, 2018	Feb 10, 2026	4 AOPs 383: Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis 414: Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway 415: Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway 494: AhR activation leading to liver fibrosis
2408	Increase, Adipose lipolysis Short Name Increase, Adipose lipolysis	0	Tissue	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
2406	Increase, Regenerative nodule formation Short Name Increase, Regenerative nodule formation	0	Tissue	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
134	Increase, Kupffer cell activation Short Name Increase, Kupffer cell activation	1	Cellular	Nov 29, 2016	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
344	Increase, Liver fibrosis Short Name Increase, Liver fibrosis	1	Organ	Nov 29, 2016	Feb 11, 2026	11 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 383: Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis 494: AhR activation leading to liver fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
1271	Increase, Transforming growth factor-beta signaling Short Name Activation of TGF-β signaling	0	Molecular	Feb 15, 2017	Feb 11, 2026	7 AOPs 206: Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
459	Increase, Liver steatosis Short Name Increase, Liver steatosis	1	Organ	Nov 29, 2016	Feb 11, 2026	21 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis 36: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 285: Inhibition of N-linked glycosylation leads to liver injury 318: Glucocorticoid Receptor activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis 518: Liver X Receptor (LXR) activation leads to liver steatosis 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis 232: NFE2/Nrf2 repression to steatosis 57: AhR activation leading to hepatic steatosis 494: AhR activation leading to liver fibrosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2119	Increase, Insulin resistance Short Name Increase, Insulin resistance	1	Organ	Apr 3, 2023	Feb 11, 2026	7 AOPs 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 454: PM2.5-related AOP frameworks on liver diseases 493: ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
1815	Increase, Endoplasmic reticulum stress Short Name Increase, ER stress	0	Cellular	Nov 2, 2020	Feb 11, 2026	4 AOPs 362: Immune mediated hepatitis 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress